Nanotechnology drug delivery is a growing field and is witnessing increasing acceptance in health care applications. Nanotechnology drug delivery is widely used in the health care industry in applications such as neurology, anti-infective, cardiovascular disorders, and others. One important and active application area of nanotechnology drug delivery systems is to transport drugs to the final location of therapeutic intervention within the body. The nanotechnology drug delivery market is witnessing rapid growth due to increase in research and development activities in nanotechnology to develop novel nano-medicine. According to Eurostat comprehensive data, the nano-medicine industry in the EU includes 97 startups, 64 SMEs, and 38 large pharmaceutical or medical device companies. Furthermore, technological advancements and rising interest of key companies to invest in nanotechnology boost market growth. For instance, in 2011–2012, Pfizer, Inc., Amgen, Inc., and AstraZeneca signed agreements to collaborate with BIND Therapeutics to develop nano-medicines. These initiatives are expected to fuel the growth of the nanotechnology drug delivery market in the near future. However, stringent regulatory scenario and high development cost of medicines through nanotechnology are likely to hamper market growth during the forecast period. The global nanotechnology drug delivery market was valued at US$ 41,062.5 Mn in 2014 and is projected to reach US$ 118,527.2 Mn by 2023, expanding at a CAGR of 12.5% from 2015 to 2023.
Based on technology, the global nanotechnology drug delivery market has been segmented into nanocrystals, nanoparticles, liposomes, micelles, nanotubes, and others. The nanoparticles segment dominated the global nanotechnology drug delivery market in 2014. The segment dominated the market as key nanoparticles such as dendrimers, gold nanoparticles, and fullerenes are used in pharmaceutical drug delivery. The nanotubes segment is expected to expand at the highest CAGR during the forecast period from 2015 to 2023.
Based on application, the market has been segmented into neurology, oncology, cardiovascular/physiology, anti-inflammatory/immunology, anti-infective, and others. Anti-infective was the largest application segment of the nanotechnology drug delivery market due to rising prevalence of community-based and hospital-based infections.
Geographically, North America dominated the global nanotechnology drug delivery market in 2014. Rising incidence of chronic diseases such as cancer and diabetes in the region fueled the growth of the nanotechnology drug delivery market in North America. Europe accounted for the second largest share of the market in 2014 owing to the favorable growth conditions for pharmaceutical and biotechnology manufacturers due to affordability for branded nanotechnology products by consumers. However, the market in Latin America is estimated to expand at the highest CAGR during the forecast period. High market growth in this region is due to increasing interest of leading companies such as Novartis and Johnson & Johnson to establish their presence in countries in Latin America such as Brazil and Mexico.
Key players having presence in the global nanotechnology drug delivery market are AbbVie, Inc., Amgen, Inc., Celgene Corporation, Johnson & Johnson, Merck & Co., Inc., and Novartis International AG, among others.
Nano-technology field has a potential to make significant impact on healthcare by delivering disease diagnosis, monitoring, implants, regenerative medicines and drug delivery, drug discovery for biomedicine. Since last few years, significant progress has been made in the field of nano-medicine (i.e. nano-technology), resulting in a number of products, including therapeutics and imaging agents, enabling more effective and less toxic therapeutic and diagnostic interventions. This progress have resulted in development of innovative diagnostic and therapeutic personalized nano-medicine treatment. Rapidly expanding areas of research and development to develop novel nano-medicine is expected to drive the market growth in future. Moreover, one of the major factor assisting market growth is the rising prevalence of infectious diseases and cancer, developing nanotechnology research, and rising demand for novel drug delivery systems. However, high cost coupled with stringent regulatory scenario hampers the market growth to some extent.
A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global nanotechnology drug delivery market and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, technology trend, industry challenges, sale data for some non-marketed nano-pharmaceuticals, patent landscape, and market share analysis by key players (%) operating in the nanotechnology drug delivery market.
Based on technology, the global nanotechnology drug delivery market has been segmented into nanocrystals, nanoparticles, liposomes, micelles, nanotubes and others. The market for these technology types has been extensively analyzed based on sales revenue of the various leading marketed products developed by the manufacturers. The market size and forecast in terms of USD million for each technology has been provided for the period from 2013 to 2023. The report on the nanotechnology drug delivery market also provides compound annual growth rate (CAGR %) for each of the market segments mentioned above for the forecast period from 2015 to 2023, considering 2014 as the base year.
Additionally, the report also categorized based on different application area of nanotechnology such as neurology, oncology, cardiovascular/physiology, anti-inflammatory/immunology, anti-infective and other applications. The market size and forecast in terms of USD million for each application has been provided for the period from 2013 to 2023. The report also provides compound annual growth rate (CAGR %) for each application segments mentioned above for the forecast period from 2015 to 2023, considering 2014 as the base year.
Geographically, the global nanotechnology drug delivery market has been categorized into North America, Europe, Asia-Pacific, Latin America and Rest of the World (RoW). The market size and forecast for each of these regions have been provided for the period from 2013 to 2023 along with CAGR (%) for the forecast period from 2013 to 2023. The research study also incorporates the competitive scenario of major players in these regions.
The report concludes with the profiles of major players in the global nanotechnology drug delivery market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include AbbVie, Inc., Amgen Inc., Celgene Corporation, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Perrigo Company plc and others.
The global nanotechnology drug delivery market is segmented as follows:
- Global Nanotechnology Drug Delivery Market, by Technology
- Gold Nanopartilces
- Global Nanotechnology Drug Delivery Market, by Applications
- Other Applications
- Global Nanotechnology Drug Delivery Market, by Geography
- North America
- Asia Pacific
- Latin America (LATAM)
- Rest of the World (RoW)